Pages that link to "Q46078828"

The following pages link to A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients (Q46078828):

Displaying 44 items.

• Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Q24202939) (← links)
• Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence (Q26777842) (← links)
• Treatment of neurodevelopmental disorders in adulthood (Q27000307) (← links)
• Rehabilitation of Motor Function after Stroke: A Multiple Systematic Review Focused on Techniques to Stimulate Upper Extremity Recovery (Q27314590) (← links)
• The role of citicoline in neuroprotection and neurorepair in ischemic stroke. (Q33772185) (← links)
• Blood Pressure and Penumbral Sustenance in Stroke from Large Vessel Occlusion. (Q33863549) (← links)
• Dynamic plasticity: the role of glucocorticoids, brain-derived neurotrophic factor and other trophic factors (Q34295880) (← links)
• Emerging treatments for motor rehabilitation after stroke (Q35171322) (← links)
• Stroke Recovery: Surprising Influences and Residual Consequences (Q35249075) (← links)
• The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials (Q35985956) (← links)
• Effect of Antidepressants on the Course of Disability Following Stroke (Q36590600) (← links)
• Chronic Enhancement of Serotonin Facilitates Excitatory Transcranial Direct Current Stimulation-Induced Neuroplasticity (Q36690635) (← links)
• Pharmacologic approaches to cerebral aging and neuroplasticity: insights from the stroke model (Q36755173) (← links)
• Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. (Q36840239) (← links)
• Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice (Q37562221) (← links)
• Advances in cerebrovascular disease research in the last year (Q37813049) (← links)
• Post-stroke depression: mechanisms, translation and therapy (Q37986218) (← links)
• Use of antidepressant medications to improve outcomes after stroke (Q38069504) (← links)
• Pharmacological therapies to enhance motor recovery and walking after stroke: emerging strategies (Q38130552) (← links)
• Vascular cognitive impairment and post-stroke cognitive deficits (Q38165826) (← links)
• Post-stroke depression and the aging brain (Q38269517) (← links)
• Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. (Q38377387) (← links)
• Safety of selective serotonin reuptake inhibitor treatment in recovering stroke patients (Q38402064) (← links)
• Fluoxetine Maintains a State of Heightened Responsiveness to Motor Training Early After Stroke in a Mouse Model (Q40621009) (← links)
• Neuronal plasticity and neurotrophic factors in drug responses (Q41842609) (← links)
• Pharmacological augmentation of motor recovery after stroke: antidepressants for non-depressed patients? (Q46095309) (← links)
• Cerebrolysin and early neurorehabilitation in patients with acute ischemic stroke: a prospective, randomized, placebo-controlled clinical study (Q47552593) (← links)
• Neuroplasticity and behavioral effects of fluoxetine after experimental stroke (Q47783283) (← links)
• Pharmacotherapy and motor recovery after stroke. (Q47975906) (← links)
• Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial (Q48322937) (← links)
• Effects of Central Nervous System Drugs on Recovery After Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (Q48325183) (← links)
• Probing modifications of cortical excitability during stroke recovery with navigated transcranial magnetic stimulation. (Q48604125) (← links)
• Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke (Q48873193) (← links)
• Selective serotonin-reuptake inhibitors and recovery after stroke (Q48932536) (← links)
• Antidepressants in the treatment of stroke (Q49110624) (← links)
• Prestroke selective serotonin reuptake inhibitor use and functional outcomes after ischaemic stroke. (Q54943050) (← links)
• Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke (Q57796687) (← links)
• Hyperforin improves post-stroke social isolation‑induced exaggeration of PSD and PSA via TGF-β (Q58616499) (← links)
• Potential Role of Selective Serotonin Reuptake Inhibitors in Improving Functional Outcome after Stroke (Q60768423) (← links)
• Hyperforin Promotes Post-stroke Neuroangiogenesis via Astrocytic IL-6-Mediated Negative Immune Regulation in the Ischemic Brain (Q64248594) (← links)
• [Drugs for improvement of motor deficits after stroke] (Q88335954) (← links)
• Which Patients Are Prescribed Escitalopram?: Predictors for Escitalopram Prescriptions and Functional Outcomes among Patients with Acute Ischemic Stroke (Q88907293) (← links)
• Effects of remote limb ischemic conditioning on muscle strength in healthy young adults: A randomized controlled trial (Q89527123) (← links)
• Antidepressant pharmacotherapy and poststroke motor rehabilitation: A review of neurophysiologic mechanisms and clinical relevance (Q92112193) (← links)